OBJECTIVE: To characterize the hospitalization and death rates among patients with inflammatory arthritis (IA) affected by coronavirus disease 2019 (COVID-19) and to analyze the associations of comorbidities and immunomodulatory medications with infection outcomes. METHODS: Data on clinical and demographic features, maintenance treatment, disease course, and outcomes in individuals with IA (rheumatoid arthritis and spondyloarthritis) with symptomatic COVID-19 infection were prospectively assessed via web-based questionnaire followed by individual phone calls and electronic medical record review. Baseline characteristics and medication use were summarized for hospitalized and ambulatory patients, and outcomes with the different medication classes were compared using multivariable logistic regression. RESULTS: A total of 103 patients with IA were included in the study (80 with confirmed COVID-19 and 23 with high suspicion of COVID-19). Hospitalization was required in 26% of the participants, and 4% died. Patients who were hospitalized were significantly more likely to be older (P < 0.001) and have comorbid hypertension (P = 0.001) and chronic obstructive pulmonary disease (P = 0.02). IA patients taking oral glucocorticoids had an increased likelihood of being admitted for COVID-19 (P < 0.001), while those receiving maintenance anticytokine biologic therapies did not. CONCLUSION: Among patients with underlying IA, COVID-19 outcomes were worse in those receiving glucocorticoids but not in patients receiving maintenance anticytokine therapy. Further work is needed to understand whether immunomodulatory therapies affect COVID-19 incidence.
OBJECTIVE: To characterize the hospitalization and death rates among patients with inflammatory arthritis (IA) affected by coronavirus disease 2019 (COVID-19) and to analyze the associations of comorbidities and immunomodulatory medications with infection outcomes. METHODS: Data on clinical and demographic features, maintenance treatment, disease course, and outcomes in individuals with IA (rheumatoid arthritis and spondyloarthritis) with symptomatic COVID-19infection were prospectively assessed via web-based questionnaire followed by individual phone calls and electronic medical record review. Baseline characteristics and medication use were summarized for hospitalized and ambulatory patients, and outcomes with the different medication classes were compared using multivariable logistic regression. RESULTS: A total of 103 patients with IA were included in the study (80 with confirmed COVID-19 and 23 with high suspicion of COVID-19). Hospitalization was required in 26% of the participants, and 4% died. Patients who were hospitalized were significantly more likely to be older (P < 0.001) and have comorbid hypertension (P = 0.001) and chronic obstructive pulmonary disease (P = 0.02). IA patients taking oral glucocorticoids had an increased likelihood of being admitted for COVID-19 (P < 0.001), while those receiving maintenance anticytokine biologic therapies did not. CONCLUSION: Among patients with underlying IA, COVID-19 outcomes were worse in those receiving glucocorticoids but not in patients receiving maintenance anticytokine therapy. Further work is needed to understand whether immunomodulatory therapies affect COVID-19 incidence.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Alexis Ogdie; YiDing Yu; Kevin Haynes; Thorvardur Jon Love; Samantha Maliha; Yihui Jiang; Andrea B Troxel; Sean Hennessy; Steven E Kimmel; David J Margolis; Hyon Choi; Nehal N Mehta; Joel M Gelfand Journal: Ann Rheum Dis Date: 2014-10-28 Impact factor: 19.103
Authors: Peter Richardson; Ivan Griffin; Catherine Tucker; Dan Smith; Olly Oechsle; Anne Phelan; Michael Rawling; Edward Savory; Justin Stebbing Journal: Lancet Date: 2020-02-04 Impact factor: 79.321
Authors: Kristin M D'Silva; Naomi Serling-Boyd; Rachel Wallwork; Tiffany Hsu; Xiaoqing Fu; Ellen M Gravallese; Hyon K Choi; Jeffrey A Sparks; Zachary S Wallace Journal: Ann Rheum Dis Date: 2020-05-26 Impact factor: 27.973
Authors: Ana Rita Cruz-Machado; Sofia C Barreira; Matilde Bandeira; Marc Veldhoen; Andreia Gomes; Marta Serrano; Catarina Duarte; Maria Rato; Bruno Miguel Fernandes; Salomé Garcia; Filipe Pinheiro; Miguel Bernardes; Nathalie Madeira; Cláudia Miguel; Rita Torres; Ana Bento Silva; Jorge Pestana; Diogo Almeida; Carolina Mazeda; Filipe Cunha Santos; Patrícia Pinto; Marlene Sousa; Hugo Parente; Graça Sequeira; Maria José Santos; João Eurico Fonseca; Vasco C Romão Journal: Front Med (Lausanne) Date: 2022-06-13
Authors: Lai-Shan Tam; Yoshiya Tanaka; Rohini Handa; Zhanguo Li; Jose Paulo Lorenzo; Worawit Louthrenoo; Catherine Hill; Kevin Pile; Philip C Robinson; Leonila F Dans; Li Yang Hsu; Sang-Min Lee; Jiacai Cho; A T M Tanveer Hasan; Babur Salim; Saba Samreen; Syahrul Sazliyana Shaharir; Priscilla Wong; Jeffrey Chau; Debashish Danda; Syed Atiqul Haq Journal: Int J Rheum Dis Date: 2021-05-04 Impact factor: 2.454
Authors: Esam Abualfadl; Faten Ismail; Rawhya R El Shereef; Eman Hassan; Samar Tharwat; Eman F Mohamed; Essam A Abda; Ahmed R Radwan; Rasha M Fawzy; Abdel Hafeez Moshrif; Rasha Abdel Noor; Soha Senara; Mervat I Abd Elazim; Nouran M Abaza; Hala A Raafat; Iman I El-Gazzar; Dina H El-Hammady; Nevin Hammam; Tamer A Gheita; Reem El-Mallah Journal: Rheumatol Int Date: 2020-11-01 Impact factor: 2.631
Authors: Amit Saxena; Allison Guttmann; Mala Masson; Mimi Y Kim; Rebecca H Haberman; Rochelle Castillo; Jose U Scher; Kristina K Deonaraine; Alexis J Engel; H Michael Belmont; Ashira D Blazer; Jill P Buyon; Ruth Fernandez-Ruiz; Peter M Izmirly Journal: Lancet Rheumatol Date: 2021-05-27
Authors: David Simon; Koray Tascilar; Arnd Kleyer; Filippo Fagni; Gerhard Krönke; Christine Meder; Peter Dietrich; Till Orlemann; Thorsten Kliem; Johanna Mößner; Anna-Maria Liphardt; Verena Schönau; Daniela Bohr; Louis Schuster; Fabian Hartmann; Moritz Leppkes; Andreas Ramming; Milena Pachowsky; Florian Schuch; Monika Ronneberger; Stefan Kleinert; Axel J Hueber; Karin Manger; Bernhard Manger; Raja Atreya; Carola Berking; Michael Sticherling; Markus F Neurath; Georg Schett Journal: Arthritis Rheumatol Date: 2022-03-23 Impact factor: 10.995